Erratum: Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation (Oncotarget. (2020) 11 (2137–2140) DOI: 10.18632/oncotarget.27598)
- Molina-Cerrillo, J.
- Alonso-Gordoa, T.
- Carrato, A.
- Grande, E.
ISSN: 1949-2553
Argitalpen urtea: 2022
Alea: 13
Zenbakia: 1
Orrialdeak: 1245
Mota: Hutsen zuzenketa
